biotech-executive
(22)
John McManus and the Business of Being Ready
For more than 15 years, the biotechnology executive has worked where drug development meets public preparedness - a patient business built around threats everyone hopes will remain hypothetical.
Vikram Joshi and the Business of Knowing What to Spare
A materials engineer learned to value experiments that fail. Two decades later, that habit sits at the commercial edge of a cell-therapy platform built to make an exquisitely difficult distinction: tumor from normal tissue.
Justin Chickles Is Building a Biotech on the Art of Removing Friction
After more than 25 years moving between large healthcare companies and lean startups, the Glycyx CEO has learned that biotech progress often depends on a less glamorous skill: turning a complicated premise into the next clear, fundable step.
Jay Stamatis Traded the Mega-Deal Table for a Biotech With Two Shots on Goal
After more than eight years shaping AbbVie’s pipeline, the history major turned biotech dealmaker is now running MBrace Therapeutics - where the wager is on novel targets, disciplined development and knowing which risks are worth taking.
Karl Beutner Spent 350 Trials Learning What Biotech Founders Usually Learn Too Late
Before he became a biotech founder, Karl Beutner built a practice, ran more than 350 clinical trials and helped guide over a dozen products to approval. DermBiont is the latest chapter in a career spent turning small, testable decisions into durable progress.
Roland Green Keeps Turning Lab Bench Problems Into Companies
Before Roland Green built antibody platforms, he wrote poetry, chased snow, and taught English in Prague. The same curiosity later turned a graduate-school workaround into NimbleGen - and now shapes how Invenra moves complex biology from bench to business.
Craig Gibbs Has Spent a Career Turning Lab Logic Into Biotech Momentum
From a protein-engineering bench to the CEO seat at Vivace Therapeutics, Craig Gibbs has built a career around one stubborn question: how does promising biology become a drug program that can actually move?
Amy Mahery Learned the Business by Moving Toward the Hard Parts
Her career began with a rugby conversation in an airport lounge. Two decades later, the Moderna marketing chief still treats curiosity, range and access to information as operating tools.
Chris McNulty
Chris McNulty is the interim CEO of Ring Therapeutics, a Cambridge, Massachusetts biotech developing genetic medicines that use commensal anelloviruses as delivery vectors. An MIT-trained engineer with a Harvard MBA, he joined Ring in May 2023 as Chief Financial Officer and Head of Corporate Strategy and stepped up to lead the company in December 2024. Over more than 15 years in pharma and biotech finance, he has closed financing transactions worth more than $300 million across companies including VBI Vaccines, InVivo Therapeutics, Repligen, and Genzyme.
Allison Luo
Allison Luo, MD is the Chief Medical Officer of Mirador Therapeutics, a San Diego precision-medicine company that launched in 2024 with more than $400 million to attack immuno-fibrotic diseases using its Mirador360 development engine. A physician scientist with more than two decades in clinical development, she was CMO of Prometheus Biosciences before Merck bought it for $10.8 billion, and has since reassembled with that team to build Mirador. She sits on the board of Triveni Bio and has held medical-leadership roles across Ventyx, Biora, Iveric Bio and Bristol Myers Squibb.
Paul Scagnetti
Paul Scagnetti is the CEO of ONI (Oxford Nanoimaging), the Oxford spin-out behind the Nanoimager, the first desktop super-resolution microscope to see single molecules at 20 nanometer resolution. A mechanical engineer with a PhD from MIT and 25+ years in life sciences and instruments, he left a job he loved at Illumina in February 2023 to bet that making Nobel-grade imaging simple enough for any lab would change drug discovery. In January 2025 he shipped the Aplo Scope, which he calls the biggest launch in ONI's history.
Philina Lee
Philina Lee, PhD is the Chief Executive Officer of AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer built on a proprietary Lead-212 platform. A biopharmaceutical executive with more than two decades in oncology, she was Chief Commercial Officer at Blueprint Medicines (acquired by Sanofi for roughly $9.5 billion) and earlier helped build the organization at Algeta that launched Xofigo, the first approved alpha therapy. Trained as a cell biologist at MIT, she took the AdvanCell helm on January 1, 2026 to lead the company's US expansion from a new Boston-area headquarters and advance its lead candidate 212Pb-ADVC001 for prostate cancer.
Scott Greenberg
Scott Greenberg is the Chief Business Officer of Nura Bio, a clinical-stage biopharmaceutical company in South San Francisco building small-molecule drugs to stop nerves from dying. He joined in February 2025 to steer business development and corporate strategy as the company pushes its lead SARM1 inhibitor, NB-4746, into the clinic. He arrives with more than two decades crossing the line between finance and biology - a Goldman Sachs banking start, more than a decade at Celgene, an operations leadership role at Roivant Sciences, and a stint as Chief Operating Officer at Aro Biotherapeutics. He studied both Finance and the Biological Basis of Behavior at the University of Pennsylvania before an MBA at Harvard.
Aditya Venugopal
Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.
Alvin Luk
Alvin Luk is a biotech executive, neuroscientist and entrepreneur with more than three decades in global drug development. He is President & Chief Medical Officer (Group) and U.S. CEO of HanchorBio, a clinical-stage immunology and immuno-oncology company building Fc-based designer biologics, and co-founder and CEO of CRISPR gene-editing company HuidaGene Therapeutics. Across his career he has contributed to roughly two dozen approved products and more than 250 global regulatory submissions, including LUXTURNA, the first FDA-approved gene therapy. A 2025 TIME100 Health honoree, he wants to turn HanchorBio into the 'Genentech of Asia.'
Darrin Miles
Darrin Miles is the President and CEO of Nested Therapeutics, a Cambridge, Massachusetts precision oncology company that launched in 2022 with $125 million in financing to hunt for cancer-driving mutations hiding in plain sight. A commercialization leader with more than two decades in healthcare, Miles spent 14 years at Genentech shepherding landmark cancer brands and later served as Chief Commercial Officer at Agios Pharmaceuticals, where he helped bring the first mutant-IDH therapies to acute myeloid leukemia patients. At Nested, he is translating computational biophysics, genomics, and chemical biology into drugs aimed at targets the rest of the field calls undruggable.
Han Lee
Han Lee, Ph.D., is co-CEO of Vibrant Therapeutics, a clinical-stage biotech building logic-gated, conditionally activated antibody prodrugs designed to switch on only inside diseased tissue. A Yale-trained geneticist with an MBA who can read a sequencing run and a term sheet with equal fluency, Lee spent 15 years as the finance and dealmaking engine behind cell-therapy companies - Arcellx, Neogene, and ImmPACT Bio - steering more than 75 transactions worth billions, including two startup exits to AstraZeneca and Lyell Immunopharma. In January 2026 he joined founder Larry Wang to scale Vibrant globally and push its lead masked T-cell engager, VIB305, into the clinic.
Jason Cole
Jason F. Cole is the founding CEO and board member of Zag Bio, a Cambridge, Massachusetts biotech that launched in October 2025 with $80 million to develop thymus-targeted medicines for autoimmune diseases, starting with Type 1 diabetes. A lawyer by training with a J.D. from Columbia and an A.B. in Government from Dartmouth, Cole has spent more than two decades in biotech operations and finance. At bluebird bio he helped grow the company from roughly 100 to 1,200 employees, raised over $3.7 billion in equity financings, and helped deliver multiple first-in-class gene and cell therapies to patients. He most recently led SalioGen Therapeutics as CEO and Board Chair, and serves as Vice Chair of the MassBio board.
Marguerite Hutchinson
Marguerite Hutchinson, J.D., is the Chief Business Officer of STORM Therapeutics, a Cambridge, UK clinical-stage biotech advancing the first RNA methyltransferase inhibitor into clinical development. A Harvard graduate and lawyer by training, she has spent more than a decade turning early science into deals - building licensing partnerships with Roche, Merck, AstraZeneca, AbbVie and Cancer Research UK, founding and funding a UCSF spin-out, and steering a first-in-class cancer drug through to approval. She was named one of the Top 25 Women Leaders in Biotechnology.
Tom Smart
Tom Smart is a biotech executive with a 25-year run of taking cancer companies from the lab bench to Wall Street and back again. He currently leads Actym Therapeutics, a cancer-immunotherapy company building bacteria-delivered gene therapies, after a career that ran through AnaptysBio, XOMA, Cell Genesys and Genetics Institute. He helped shepherd the PD-1 checkpoint inhibitor that became GSK's Jemperli, founded and sold an antifungal company, and is named in industry records as a CEO and board member at oncolytic-virus company Seneca Therapeutics. His specialty is the unglamorous middle: financings, partnerships, IPOs and acquisitions that decide whether a promising molecule ever reaches a patient.
John McHutchison
John McHutchison, AO, MD is the CEO and Chairman of Tune Therapeutics, a pioneering epigenome editing company based in Durham, NC. An internationally acclaimed hepatologist and drug developer, McHutchison spent nearly a decade at Gilead Sciences as Chief Scientific Officer, where he led the development of transformative hepatitis C cures used by over 3.2 million people worldwide, including Sovaldi and Harvoni. Now at Tune, he is steering the company's TEMPO epigenome editing platform toward a new era of precision medicine for chronic and complex diseases.
David Lockhart
David J. Lockhart, Ph.D. is President and Chief Scientific Officer of ReCode Therapeutics, a clinical-stage biotech pioneering nonviral lipid nanoparticle (LNP) delivery of mRNA and gene-editing payloads to the lungs for genetic respiratory diseases including cystic fibrosis and primary ciliary dyskinesia. With more than 25 years in drug discovery and genomics — from co-founding Ambit Biosciences to leading science at Amicus Therapeutics — Lockhart brings rare-disease chops and deep genomics expertise to ReCode's SORT LNP platform, which has raised $345M and dosed its first patients in a Phase 1 PCD trial.